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Abstract
In this opinion the antimicrobial-resistant bacteria responsible for transmissible diseases that constitute
a threat to dog and cat health have been assessed. The assessment has been performed following a
methodology based on information collected via an extensive literature review and expert judgement.
Details of the methodology used for this assessment are explained in a separate opinion. A global
state of play of antimicrobial resistant Staphylococcus pseudintermedius, Staphylococcus aureus,
Staphylococcus schleiferi, Escherichia coli, Proteus mirabilis, Klebsiella spp., Enterobacter spp.,
Pseudomonas aeruginosa, Clostridium perfringens, Clostridioides difficile, Enterococcus faecalis and
Enterococcus faecium has been provided. Among those bacteria, EFSA identified S. pseudintermedius,
E. coli and P. aeruginosa with > 90% certainty as the most relevant antimicrobial resistant bacteria in
the EU based on the available evidence. The animal health impact of these most relevant bacteria, as
well as their eligibility for being listed and categorised within the animal health law framework will be
assessed in separate scientific opinions.
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1. Introduction
The European Food Safety Authority (EFSA) received a mandate from the European Commission to
investigate the global state of play as regards antimicrobial resistant animal pathogens that cause
transmissible animal diseases (ToR 1), to identify the most relevant bacteria in the EU (first part of ToR
2), to summarise the actual or potential animal health impact of those most relevant bacteria in the EU
(second part of ToR 2) and to perform the assessment of those bacteria to be listed and categorised
according to the criteria in Article 5, Annex IV according to Article 9, and 8 within the Regulation (EU)
2016/429 on transmissible animal diseases (‘Animal Health Law’)1 (ToR 3).
This scientific opinion presents the global state of play as regards resistant animal pathogens that
cause transmissible animal diseases (ToR 1) and the results of the assessment of the most relevant
bacteria in the EU (first part of ToR 2) for dogs and cats following the methodology described in EFSA
AHAW Panel (2021).
1.1. Background and terms of reference as provided by the requestor
The background and terms of reference (ToR) as provided by the European Commission for the
present document are reported in Sections 1.1 and 1.2 of the scientific opinion on the ad hoc method
to be followed for the assessment of animal diseases caused by bacteria resistant to antimicrobials
within the Animal Health Law (AHL) framework (EFSA AHAW Panel, 2021).
1.2. Interpretation of the terms of reference
The interpretation of the ToR is as in Sections 1.3.1 and 1.3.2 of the scientific opinion on the ad
hoc method to be followed for the assessment of animal diseases caused by bacteria resistant to
antimicrobials within the AHL framework (EFSA AHAW Panel, 2021).
The present document reports the results of the assessment of bacterial pathogens resistant to
antimicrobials in dogs and cats.
2. Data and methodologies
The methodology applied for this opinion is described in a dedicated document which details the ad
hoc method for the assessment of animal diseases caused by bacteria resistant to antimicrobials within
the AHL framework (EFSA AHAW Panel, 2021). Additional methods specific to this opinion (data
collection via an extensive literature review) are detailed below.
2.1. Extensive literature review
The process to identify the bacterial species to focus on in the extensive literature review (ELR) is
described in Section 2.1.2 in the ad hoc method for the assessment of animal diseases caused by
bacteria resistant to antimicrobials within the AHL (EFSA AHAW Panel, 2021). According to that
methodology, the following target bacterial pathogens for dogs and cats had been agreed upon by the
EFSA working group: Bordetella bronchiseptica, Clostridioides difficile, Clostridium perfringens,
Enterobacter spp., Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella
pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus
pseudintermedius and Staphylococcus schleiferi. The extensive literature review was carried out by the
University of Copenhagen under the contract OC/EFSA/ALPHA/2020/02 – LOT 1.2 On 3 November
2020, two different search strings (Appendix A) were applied in PubMed and Embase, respectively,
resulting in the identification of 1,698 unique abstracts published since 2010. Upon import into the
Rayyan software (https://rayyan.ai/terms/show), these abstracts were screened by a senior scientist
following the criteria elaborated in the protocol for the inclusion and exclusion of studies. When
available, the full text of the abstracts was downloaded into the Endnote software. In addition, the
most recent national antimicrobial resistance (AMR) monitoring reports from Denmark, Finland, France,
Germany, Norway and Sweden were downloaded. Only the latest version of the surveillance reports
was included in the review, since isolates included in these reports can be assumed to originate from
the same sampled populations and most recent versions would therefore include the most up-to-date
AMR data. AMR data in the full texts and national reports were evaluated for eligibility applying the
exclusion criteria as described in the ad hoc method followed for the assessment of animal diseases
1 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0429&rid=8
2 https://ted.europa.eu/udl?uri=TED:NOTICE:457654-2020:TEXT:EN:HTML
Assessment of animal diseases caused by bacteria resistant to antimicrobials: Dogs and cats
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2021;19(6):6680
caused by bacteria resistant to antimicrobials within the AHL framework (EFSA AHAW Panel, 2021),
with the following modifications of the standard methodology:
• Exclusion criterion 2: studies that do not report AMR data separately for cats and dogs (i.e. it
was not possible to determine the species of origin of each isolate) were considered
acceptable.
• Exclusion criterion 3: studies reporting AMR data at the genus level were accepted for
Klebsiella spp., Enterobacter spp., Enterococcus spp. and Proteus spp., since species within the
genus have the same breakpoints and data were often reported this way.
• Exclusion criterion 8: the minimum number of isolates in a study to be considered acceptable
was set at 50 for S. pseudintermedius and E. coli and at the default of 10 or more for the
other bacterial species.
Information extracted from the eligible assessed full-text reports/publications is described in the
scientific opinion describing the ad hoc method applied in the assessment (EFSA AHAW Panel, 2021).
Information on all the full-text studies that were assessed, including the reason for exclusion for
those that were excluded at the full-text screening, is presented in Appendix B.
AMR was assessed for clinically relevant antimicrobials according to the method detailed in
Section 2.1.3 of the ad hoc method for the assessment of animal diseases caused by bacteria resistant
to antimicrobials within the AHL (EFSA AHAW Panel, 2021). The list of clinically relevant antibiotics for
each target bacterial species in dogs/cats considered in this opinion are shown in Appendix C. When
more than one antimicrobial from a given class was considered eligible for inclusion in the report, the
following order of preference for each antimicrobial class and bacterial pathogen was considered:
• For methicillin in staphylococci, data for oxacillin, cefoxitin and the presence of the mecA gene
were accepted. In case data for more than one of these antimicrobials were available in the
same study, we included the one for which more isolates were tested. In case the same
number of isolates was tested for each antimicrobial, the order of preference for selection was
mecA > oxacillin > cefoxitin.
• For third-generation cephalosporins (3GC) in Enterobacterales (as an indicator of extended-
spectrum beta-lactamase (ESBL)/AmpC), the order of preference was cefpodoxime >
cefotaxime > ceftazidime > ceftriaxone > ceftiofur > other methods (data from a double disk
synergy test) (EUCAST, 2017). In case data for more than one of these antimicrobials were
available in the same study, we included the one for which more isolates were tested.
• For fluoroquinolones, the order of preference was enrofloxacin > ciprofloxacin.
• For lincosamide in staphylococci, the order of preference was clindamycin > lincomycin.
• For tetracycline in staphylococci, the order of preference was doxycycline > tetracycline >
oxytetracycline.
• For polymyxin in Pseudomonas aeruginosa, the order of preference was polymyxin B > colistin.
• For penicillin in enterococci, the order of preference was ampicillin > amoxicillin > penicillin.
• For penicillin in Clostridia, the order of preference was ampicillin > amoxicillin.
For each study, when clinical breakpoints were used, AMR data were extracted as percentages of
resistant isolates (%R) and/or as percentages of non-susceptible isolates by combining resistant and
intermediate (I) isolates (%R + I). For some drugs (e.g. sulfonamide-trimethoprim (TMP)), there is no
I category for most bacteria, hence only %R was reported. Similarly, when the presence of mecA was
used as an indication of methicillin resistance (MR), the proportion of isolates carrying the gene was
reported as the %R. Moreover, the following decisions were made when evaluating datasets:
• When no information on the I category was provided in a study, we considered that the
reported %R only comprised resistant isolates (i.e. I isolates had not been included in the R
category).
• When the percentage of susceptible isolates (%S) was reported with no information on I, it
was not possible to calculate %R. Instead, we calculated %R + I as 100% – %S.
• When %I was reported separately, we extracted that along with %R (see Appendix B), but
used only %R for the analyses of this opinion.
• When epidemiological cut-offs (ECOFFs) were used, proportions of non-wild-type isolates were
reported as %R + I, as the I category is always part of the non-wild-type population.
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3. Assessment
3.1. ToR 1: global state of play as regards resistant bacterial animal
pathogens that cause transmissible animal diseases
3.1.1. General overview of studies included and excluded
After screening 1,698 abstracts, 377 publications (including seven national AMR surveillance
reports) were selected for full-text evaluation since they were considered eligible according to the
criteria described above and in the ad hoc method for the assessment of animal diseases caused by
bacteria resistant to antimicrobials within the AHL (EFSA AHAW Panel, 2021). Of these, 279 (75%)
publications were excluded due to one or more of the exclusion criteria listed in Section 2.1.4 of the ad
hoc method for the assessment of animal diseases caused by bacteria resistant to antimicrobials within
the AHL (EFSA AHAW Panel, 2021). The most common reasons for exclusion were that the study was
performed on a subset of selected resistant clinical isolates that are thus not representative of the
degree of resistance in the pathogen (66 studies), the number of isolates included was below the pre-
established thresholds (50 for E. coli and S. pseudintermedius, 10 for the other species; 62 studies),
no availability of the full text (40 studies), and that the percentage of resistant isolates was not
provided and could not be calculated (e.g. data were provided in data charts; 37 studies) (Table 1).
After the exclusion of these references, 91 studies and the seven national reports from Denmark,
Finland, France, Norway, Germany, Sweden and Switzerland were found eligible and were
subsequently used to extract the data of interest. An overview of the number of eligible studies for
each target bacterium is shown in Table 2 (data at the genus level were accepted for Klebsiella,
Proteus and Enterococcus as explained in the methodology section).
Table 1: Main reasons for exclusion of studies after full-text evaluation affecting more than one






Study investigating AMR in a subset of resistant clinical isolates 17(b) 66
Fewer than the minimum number of isolates are included in the study 8 63
Full text not available 10 40
Percentage of resistant isolates not reported 7 38
Same animals sampled repeatedly 6 29
AMR data from multiple host species (other than cats and dogs) reported
together
2 28
Inclusion of non-clinical isolates that cannot be distinguished from clinical
isolates
5 25
AMR data reported at bacterial genus level or above (except for Klebsiella,
Enterobacter, Enterococcus and Proteus)
3 14
Minimum inhibitory concentration data reported without interpretation 12 10
Study does not follow a standard for antimicrobial susceptibility testing or a
standard is not reported
4 7
AMR data included in another included study 9 6
Study on clinical outcome related to AMR 17(b) 6
Data for individual antimicrobials cannot be extracted 1 3
Antimicrobials included are not used for treatment of host species according
to available treatment guidelines
13 3
(a): 12 other reasons listed in Appendix B affected one study each.
(b): Specified in column E, Appendix B.
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Figure 1 provides an overview of the 98 studies included (some with data on more than one
bacterial species) sorted by year of publication. Most included studies were published in 2020, which is
due to the inclusion of only the most recent national reports.
Considering geographical distribution, data from the included studies originated from 33 individual
countries (5 studies reported data from isolates collected in multiple countries). The most represented
countries were France, the United States and Italy, with 13, 12 and 11 studies including data from
isolates collected in each country, respectively (Figure 2). Altogether, Europe was the most studied
continent in the ELR, with 44 of the 98 included studies (45%) reporting AMR data for dogs and cats
in this region, with between 3 and 27 studies performed on the other continents.
Table 2: Number of eligible studies from which AMR data were extracted, by target bacterial
species













*: One study could provide information on more than one bacterial species.
Figure 1: Date of publication of the 98 studies included in the extensive literature review
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Isolates originated mostly from two main types of collection: (i) those generated through the
analysis of samples collected from a clearly defined population of dogs or cats in a clinic, hospital, farm
or similar (e.g. kennel) (n = 45 studies), and (ii) those coming from a diagnostic laboratory without
background information on patients (n = 50 studies) (the origin was unclear for the remaining three
studies).
3.1.2. AMR frequency data
The figures and tables in the following pathogen-specific sections summarise AMR frequency data
reported for dogs and cats from six continents.
It should be noted that the AMR frequency data are extremely difficult to compare, as study
design, study populations, methods, interpretive criteria, etc., vary considerably between studies. The
number of antimicrobial susceptibility testing (AST) results for any given antimicrobial extracted from
the selected references (total of 244,513, Appendix B) varied enormously between bacterial species
considered, with the first two accounting for almost 84% of all results (E. coli: 121,325; S.
pseudintermedius: 83,106) and over 1,000 AST results for only four other species (P. aeruginosa:
15,115; P. mirabilis: 11,819; S. aureus: 6,365; S. schleiferi: 4,147). The laboratory methods used to
determine the AST result also varied widely between studies, although the most common ones
(accounting for 97% of all results) were disk diffusion (125,717 determinations), broth microdilution
(88,130 results), gene identification by polymerase chain reaction (PCR) (12,292) and agar dilution
(11,267), with the remaining results often coming from a combination of some of these methods
(Appendix B).
In addition, AMR data from dogs and cats have been reported in the same tables and figures
without distinguishing between the two species. This may give rise to bias for some antibiotic/infection
combinations where breakpoints differ for dogs and cats. Therefore, the figures, tables and examples
highlighted in the text below should be interpreted and cited with caution, as all specificities of
individual studies cannot be taken into consideration. To correctly interpret information presented in
the figures or tables (e.g. a high frequency of resistance in a certain country/continent), it is strongly
recommended to consult the relevant papers and check whether results may be biased by factors such
as previous antimicrobial treatment, sampling of animals in a certain environment, or the use of
certain diagnostic methods or breakpoints.
3.1.3. Results of the ELR by bacterium
3.1.3.1. Staphylococcus pseudintermedius
Staphylococcus pseudintermedius resides in the skin and mucous membranes as a component of
the normal flora of dogs and, to a lesser extent, of cats. It is an opportunistic pathogen, which mostly
Figure 2: Geographical distribution of the 98 studies included
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causes infections associated with the integumentary system. The vast majority of canine skin infections
are caused by S. pseudintermedius. Other organs may also be affected by S. pseudintermedius, so
that it is one of the most common pathogen of canine urinary tract infections (UTIs) after E. coli. A
variety of drugs can be used to treat S. pseudintermedius infections, but lincosamides and beta-
lactams not affected by beta-lactamase are most commonly recommended for systemic treatment of
canine skin infections. Beta-lactams and other drugs like potentiated sulfonamides are also commonly
recommended first-choice drugs for UTIs. A problem with recommending beta-lactams is the recent
emergence of methicillin-resistant strains (MRSP). MRSP isolates are characterised by having the mecA
gene, which causes resistance to all veterinary beta-lactams. MRSP isolates are commonly multidrug
resistant, especially the ST71 type, which has spread globally.
In total, 44 eligible studies with ≥ 50 S. pseudintermedius isolates and results for one or more of
the relevant antibiotics (clindamycin/lincomycin, enrofloxacin/ciprofloxacin, gentamicin, doxycycline/
tetracycline, methicillin/methicillin-resistance surrogates, sulfonamide-TMP) were included. Among
these, 1, 11, 24, 3, 3 and 2 studies included isolates from Africa, Asia, Europe, Oceania, North America
and South America, respectively.
The distribution of S. pseudintermedius isolates per animal species and site of infection is shown in
Figure 3. The vast majority of isolates originated from dogs, and resistance was mostly reported
together for isolates deriving from different body sites.
Figure 4 shows, for each continent, the proportion of resistance reported in individual studies with
at least 50 S. pseudintermedius isolates. Information on proportions of resistance at country level is
given in Appendix D.
Mixed: isolates recovered from multiple sites reported together; SSTI: skin and soft tissue infections.
Figure 3: Distribution of S. pseudintermedius isolates per animal species and site of infection
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From Figure 4, it should be noted that data are reported separately as either %R or %R + I
depending on what data were available from each study. Although %R and %R + I data cannot be
directly compared, it appears that there is little difference in the proportions reported for the blue (%
R) and red (%R + I) circles. Only five studies (study IDs 52, 125, 157, 178 and 382 in Appendix B)
reported data for the I category separately, meaning both %R and %R + I data could be
differentiated. In these studies, the fraction of isolates with intermediate resistance to drugs varied
from 0% to 18% (Appendix B), suggesting that the inclusion of the %I in the %R category could lead
to significant changes in some cases. An arithmetic weighted average of resistance (no distinction
between %R and %R + I) for each drug on each continent is provided in Table 3.
Overall, resistance to all drugs varied tremendously between studies and countries and even within
countries. Such a large variation makes it difficult to emphasise one region/continent with particularly
high or low resistance levels. MR has been predicted from either resistance to oxacillin or cefoxitin or
the presence of the mecA gene. According to reports, MR is less common in Europe (average 7% of
resistant isolates) than on other continents, especially Asia, where 34% of isolates exhibited MR. There
are, however, some exceptions. For example, a study in Sri Lanka reported only 4% of isolates with
MR, and the authors also noted that this result was surprisingly low given that antimicrobials are
available over the counter in this country (Duim et al., 2018). An example of problems with data
comparison across studies is the following: (Saputra et al., 2017) reported 12% MR in Australia, higher
than the reported values of 6% MR in Denmark (DANMAP, 2019) and 2% MR in Sweden (Swedres-
Svarm, 2019). Despite having a somewhat similar study population (diagnostic lab data) and using the
same method (broth microdilution) and breakpoint (≥ 0.5 lg/mL) for interpreting oxacillin resistance,
MR in the Danish isolates may be overestimated because Australian and Swedish MRSP isolates were
confirmed by mecA PCR, whereas the Danish isolates were not characterised further. It is well known
that not all S. pseudintermedius isolates with oxacillin MIC ≥ 0.5 lg/mL are MRSP, and that was also
the case for the Australian study with 5 of 81 oxacillin-resistant isolates not having mecA. This
highlights that data from these three studies should not be readily compared, since values from
Denmark could be overestimated compared with what would have been obtained if exactly the same
methodology had been followed.
Total number of studies by continent and antimicrobial is reported on the right side. Each circle represents one
study and the size of each circle reflects how many isolates were included in the study. The colour of a circle
illustrates whether the proportion represents resistance only (red circle) or resistance merged with the intermediate
category (blue circle). The dashed lines indicate, for each antibiotic, the weighted arithmetic mean of %R (red
dashed line) or %R + I (blue dashed line). The exact percentages these lines represent are listed in Appendix E.
Figure 4: Staphylococcus pseudintermedius resistance data for each included study sorted by continent
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Resistance to the lincosamides represented by clindamycin or lincomycin was generally high,
exceeding 70% in some European and Asian studies. In Scandinavia, resistance was approximately
30%. Importantly, it was recently shown in Denmark that levels of clindamycin resistance were
significantly lower in S. pseudintermedius from samples from non-treated dogs with first-time
pyoderma than from samples from dogs submitted to the diagnostic laboratory in the absence of a
known clinical history (Larsen et al., 2015). This finding justifies the recommendation of lincosamides
for canine pyoderma in Denmark and illustrates a possible bias associated with AMR data from
diagnostic laboratories, which may yield higher levels of resistance compared with those obtained from
clinical isolates from non-treated animals due to a high probability of originating from animals that
have already been subjected to some antimicrobial treatment.
Resistance to sulfonamide-TMP combinations also varied considerably between studies, even
within Europe, ranging from 5% to 97%. One example of problems with comparing data is as follows:
the proportion of sulfonamide-TMP resistance reported in the Danish and Swedish national surveillance
reports were 6% and 9%, respectively, but the interpretation for Swedish isolates was different from
all other studies, as an ECOFF (≥ 1 lg/mL) was used instead of the human clinical breakpoint (≥ 4 lg/
mL) used in all the other studies. Since Swedres-Svarm (as one of few studies) publishes raw minimum
inhibitory contribution (MIC) data (Swedres-Svarm, 2019), it is possible to also interpret them
according to other criteria. For this example, only 4% of clinical S. pseudintermedius isolates would be
considered resistant if using the clinical breakpoint for sulfonamide-TMP. It should be noted that this is
just one example illustrating the issue of low comparability between reported AMR proportions. Similar
in-depth analyses have not been made for all other drugs reported here.
Resistance to fluoroquinolones was assessed using data for ciprofloxacin and enrofloxacin. The
former is a human drug interpreted according to human clinical breakpoints, whereas the latter is a
veterinary drug interpreted using animal-specific clinical breakpoints or ECOFFs. Although results for
these drugs are not fully comparable, studies testing both showed either identical results for the two
drugs (Saputra et al., 2017) or minor variations (Awji et al., 2012). Accordingly, ciprofloxacin was
considered a suitable alternative to enrofloxacin in the absence of data for the latter. Resistance to
fluoroquinolones was below 15% in most studies, irrespective of geographical origin (Figures 4 and 5).
However, one study from Italy (Casagrande Proietti et al., 2012) reported 94% of 70 isolates being
resistant to enrofloxacin. There was no obvious bias in that study, which also reported unusually high
levels of resistance to several other drugs.
Resistance to gentamicin was most frequently below 20%, except in two studies with proportions
around 50%. Resistance to tetracycline and doxycycline was common with most studies reporting
20–60% resistance.
Fusidic acid is only registered for topical use in dogs and cats; hence the value of AST to guide
treatment with this drug is very limited. Still, six studies tested this drug and reported resistance levels
between 0% in Japan (Onuma et al., 2012) and 38% in Norway (Norm/Norm-Vet, 2019).
Table 3: Weighted arithmetic mean, minimum and maximum proportions of resistance (%R or
%R + I) and weighted standard deviation in S. pseudintermedius for the target





















Fluoroquinolones Africa 1 278 6.9 6.9 6.9 NA
Fluoroquinolones Asia 2 311 25.1 4.5 30.8 10.8
Fluoroquinolones Europe 14 9,662 7.3 1 94.3 8.8
Fluoroquinolones Oceania 3 1,902 3.7 1 7.9 3
Fusidic acid Asia 2 296 4.7 0 27 10.3
Fusidic acid Europe 5 6,904 13.3 6.1 38 6.1
Gentamicin Africa 1 278 3.9 3.9 3.9 NA
Gentamicin Asia 3 390 19.8 6 46 13.6
Gentamicin Europe 12 10,182 8.2 1.7 58.6 6.1
Gentamicin Oceania 1 831 1 1 1 NA
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3.1.3.2. Escherichia coli
Escherichia coli is an opportunistic pathogen residing in the intestinal microbiota of animals and
humans. As in humans, E. coli is the leading cause of UTI in dogs and cats, accounting for 50–60% of
those infections. Depending on the type and severity of infection, there are various recommendations
for the treatment of E. coli infections. Typically, aminopenicillins and sulfonamides with trimethoprim
are recommended as first-choice drugs for UTIs, whereas fluoroquinolones and aminopenicillin with
clavulanic acid are common recommendations for more severe infections. Nitrofurantoin is not
registered for use in animals, but this drug, which is only suitable for treatment of UTIs due to its
pharmacokinetic properties, is regularly recommended as an alternative drug when the first choices fail
or resistance to those drugs is known. For the past two decades, extended-spectrum cephalosporinase
(ESC)-producing Enterobacterales have emerged in animals. The most common types occurring in
dogs and cats are the ESBL variants blaCTX-M-1 and blaCTX-M-15, as well as the plasmid-encoded AmpC
variant blaCMY-2. Despite the in vitro susceptibility of ESBL producers to beta-lactamase inhibitors, beta-
lactams are generally not recommended for treatment of infections caused by any ESC-producing
isolates. Furthermore, ESC producers are often co-resistant to other drugs, thus limiting treatment
options when these multidrug-resistant isolates are discovered.
In total, 37 studies with ≥ 50 E. coli isolates and results for one or more of the relevant antibiotics
(ampicillin/amoxicillin, enrofloxacin/ciprofloxacin, nitrofurantoin, sulfonamide-TMP, 3GCs) were included.
Among these, 1, 6, 18, 4, 8 and 0 studies included isolates from Africa, Asia, Europe, Oceania, North
America and South America, respectively.
The distribution of E. coli isolates per animal species and site of infection is shown in Figure 5. The





















Lincosamides Africa 1 278 31.7 31.7 31.7 NA
Lincosamides Asia 3 493 46.9 20.1 78 26.7
Lincosamides Europe 10 7,732 22.5 13 98.6 8.8
Lincosamides Oceania 2 1,069 8.8 3.3 12.6 4.6
Methicillin Asia 8 1,106 29.5 4 72.2 25.5
Methicillin Europe 23 19,909 5.8 0 41.4 4.2
Methicillin North
America
3 274 32.2 21 41 8.8
Methicillin Oceania 1 629 12.9 12.9 12.9 NA
Methicillin South
America
2 208 29.3 14.1 39.8 12.7
Sulfa/TMP Africa 1 278 13.3 13.3 13.3 NA
Sulfa/TMP Asia 1 79 60 60 60 NA
Sulfa/TMP Europe 12 9,766 11.5 5 97.1 7.9
Sulfa/TMP Oceania 2 1,069 28.5 16 37.2 10.4
Tetracyclines Africa 1 278 13.7 13.7 13.7 NA
Tetracyclines Asia 3 390 48.5 37.3 61 7.3
Tetracyclines Europe 10 4,440 25.8 20.2 95.7 10.4
Tetracyclines Oceania 1 629 22.5 22.5 22.5 NA
NA: Standard deviation cannot be calculated because only one study was included.
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Figure 6 shows, for each continent, the proportion of resistance reported in individual studies with
at least 50 E. coli isolates. Information on proportion of resistance sorted by country is given in
Appendix D.
Overall, resistance to all drugs varied tremendously between studies and countries and even within
countries. Such a large variation makes it difficult to identify any one region or continent with
particularly high or low resistance levels.
Considering the first-line antibiotics for UTIs, resistance levels were relatively low in many studies
for sulfonamide-TMP combinations (Figure 6). The average proportion of resistance to potentiated
sulfonamides was substantially higher in studies from Asia (52%) than other continents (range from
9% to 25%). Despite the many differences between studies, this difference appears genuine, as most
studies used the same human CLSI breakpoint. One exception is the Swedish national report using
Mixed: isolates recovered from multiple sites reported together; SSTI: skin and soft tissue infections.
Figure 5: Distribution of E. coli isolates per animal species and site of infection
Total number of studies by continent and antimicrobial is reported on the right side. Each circle represents one
study and the size of each circle reflects how many isolates were included in the study. The colour of a circle
illustrates whether the proportion represents resistance only (red circle) or resistance merged with intermediate
(blue circle). The dashed lines indicate, for each antibiotic, the weighted arithmetic mean of %R (red dashed line)
or %R + I (blue dashed line). The exact percentages these lines represent are listed in Appendix E.
Figure 6: Escherichia coli resistance data for each included study sorted by continent
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ECOFFs with a cut-off of > 1 mg/L for non-susceptibility (Swedres-Svarm, 2019). Despite this being
twice as low as the CLSI breakpoint for resistance, only 5% of E. coli from dog and 3% from cat
isolates in Sweden were resistant to this combination.
Resistance to aminopenicillins, another first-line agent for UTIs, was somewhat higher than for
sulfonamide-TMP combinations. Data for ampicillin should, however, be interpreted with caution, as
CLSI has very different veterinary breakpoints for UTIs (> 8 mg/L) and skin and soft tissue infections
(SSTIs) (> 0.5 mg/L). In that regard, it was not always possible to determine whether data from a
study with isolates of mixed origin were interpreted according to appropriate breakpoints or if only the
UTI or SSTI/skin breakpoint was used. It is, however, clear that a few studies with isolates from skin
(Ludwig et al., 2016; de Jong et al., 2020) reported 100% resistance to ampicillin for E. coli. This is a
logical finding, since the very low CLSI SSTI/skin breakpoint is 16 times lower than the ECOFF (8 mg/
L), and therefore even wild-type organisms would be considered clinically resistant. Some studies used
the human CLSI breakpoint for ampicillin, which is > 32 mg/L; hence resistance data from these
studies are not comparable to studies using veterinary breakpoints or ECOFFs. One final reservation is
that the CLSI breakpoint for cats is > 0.5 mg/L, irrespective of isolate origin, meaning no separate
breakpoint for UTIs. Taken together, comparing susceptibility data for aminopenicillins is extremely
complex, and Figure 6 is not able to give a comprehensive overview. Instead, studies must be
assessed in more detail, also taking into account isolate origin and the other factors that vary between
studies.
The breakpoints for amoxicillin–clavulanic acid are the same as for aminopenicillins without
beta-lactamase inhibitors, hence there are the same challenges of interpretation and comparison
across studies. As expected, the addition of the beta-lactamase inhibitor leads to higher susceptibility.
In fact, resistance levels to amoxicillin–clavulanic acid in North America, Europe and Asia were around
half of those observed for aminopenicillins alone (Table 4).
Resistance to 3GCs varied but was generally lower than for other antimicrobials considered here,
and never exceeded 35%. The 3GCs were included mainly with the purpose of assessing levels of ESC-
resistant E. coli, but not all of the 3GCs are equally suited for the purpose, and some are more likely to
detect one ESC resistance gene over another. As explained in the data and methodologies section, if a
study lacked resistance data for all five target 3GCs, the proportion of ESBLs was calculated based on
double disk synergy testing. Considering the diversity of data included under ‘3GC’ in Figure 6 and
Table 4, data are rather incomparable. Despite this reservation, it is clear that 3GC resistance varies
largely between studies – from 0% in Taiwan (Chang et al., 2015) and Norway (Norm/Norm-Vet, 2019)
to 33% in Japan (Tsuyuki et al., 2018).
Resistance to fluoroquinolones was assessed using data for ciprofloxacin and enrofloxacin.
Although results for these drugs are not fully comparable, studies testing both agents showed fairly
similar results with only minor variation between them (a few percentage points, data not shown).
Therefore, in the following, both drugs are considered on equal terms. More than half of the studies
reported less than 10% resistance to fluoroquinolones, and particularly low resistance levels (1–3%)
were reported in three studies from Oceania. Generally, the highest levels of fluoroquinolone resistance
were reported by the six Asian studies, with an average of 45%. Unlike for the other drugs, it
therefore appears that there is a geographical trend concerning resistance to fluoroquinolones in
E. coli.
Susceptibility of E. coli to nitrofurantoin was only tested in two studies from Sweden (Windahl
et al., 2014; Swedres-Svarm, 2019). Resistance levels were less than 2%, but the lack of data for
other countries makes it difficult to extrapolate those data beyond Sweden.
Table 4: Weighted arithmetic mean, minimum and maximum proportion of resistance (%R or %R + I)





















3GC Asia 5 599 20 0 33.3 11.6
3GC Europe 13 9,350 6.5 0.2 71.4 10.4
3GC North
America
4 4,444 13.3 1.8 22 3.2
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3.1.3.3. Pseudomonas aeruginosa
Pseudomonas aeruginosa is an environmental organism that can reside in the intestine but is more
commonly found on the integumentary system of human and animal hosts, with a preference for moist
areas. It can cause various infections, but by far the most important in dogs is otitis externa. Its ability
to produce biofilm and its intrinsic resistance are among the reasons why P. aeruginosa otitis in dogs
can be very severe and difficult to treat. Mostly, topical treatment is recommended for P. aeruginosa
otitis externa, but systemic treatment is sometimes necessary due to the severity of the infection.
Fluoroquinolones are recommended for systemic treatment of these infections, but alternatives like
gentamicin and polymyxin B or colistin are also possible. The main challenge of the latter three options
is that they are not registered for systemic use in dogs; hence, the cascade rule must be employed.
In total, 20 studies with ≥ 10 P. aeruginosa isolates and results for one or more of the relevant
antibiotics (enrofloxacin/ciprofloxacin, gentamicin, colistin/polymyxin B) were included. Among these
studies 1, 5, 9, 1, 1 and 3 included isolates from Africa, Asia, Europe, Oceania, North America and
South America, respectively.
The distribution of P. aeruginosa per animal species and site of infection is depicted in Figure 7. The





















3GC Oceania 1 855 8.4 8.4 8.4 NA
Aminopenicillins Africa 1 164 70.1 70.1 70.1 NA
Aminopenicillins Asia 4 408 45 30 59.1 11.2
Aminopenicillins Europe 12 8,716 33.1 12.1 100 19
Aminopenicillins North
America
8 12,486 37.2 8.8 62.9 10
Aminopenicillins Oceania 2 1,013 37.8 37.2 41 1.4
Amox/Clav Africa 1 163 58.3 58.3 58.3 NA
Amox/Clav Asia 3 294 15.8 2.6 30.7 13.4
Amox/Clav Europe 12 13,382 18.6 0 100 17.3
Amox/Clav North
America
7 12,408 22.2 2.7 40 11.4
Amox/Clav Oceania 3 2,121 35.1 11.8 67.2 26.6
Fluoroquinolones Africa 1 167 16.2 16.2 16.2 NA
Fluoroquinolones Asia 6 703 45 5.3 92.5 31.4
Fluoroquinolones Europe 14 8,820 8.3 2.1 39.3 9.6
Fluoroquinolones North
America
7 12,405 10.5 1.8 19.6 5.8
Fluoroquinolones Oceania 4 2,267 4.4 2.3 8 2.3
Nitrofurantoin Europe 2 2,056 1.1 1 1.6 0.2
Sulfa/TMP Africa 1 166 24.7 24.7 24.7 NA
Sulfa/TMP Asia 5 563 52.4 25 77.5 21.4
Sulfa/TMP Europe 12 14,481 11.5 4.3 61.2 9
Sulfa/TMP North
America
6 12,030 10.1 0 17.9 5
Sulfa/TMP Oceania 2 1,264 8.9 8 15 2.3
NA: Standard deviation cannot be calculated because only one study is included.
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Figure 8 shows, for each continent, the proportion of resistance reported in individual studies with
at least 10 P. aeruginosa isolates, whereas average values are shown in Table 6. Information on
proportion of resistance sorted by country is given in Appendix D.
For fluoroquinolones, resistance varied a lot between studies. It is noteworthy that one study (Arais
et al., 2016) reported a large difference in proportion of resistance to enrofloxacin (26.0%) and
ciprofloxacin (4.8%). By including intermediate isolates, the figures changed to 77.2% and 7.7%,
respectively. A large proportion of isolates (47–82%) in three other studies (Mekic et al., 2011; Ludwig
et al., 2016) also showed intermediate resistance to enrofloxacin. These findings suggest that for P.
aeruginosa (i) the two fluoroquinolones are not readily comparable, and (ii) %R cannot be compared with
%R + I for enrofloxacin. To illustrate this, the 73.0% enrofloxacin resistance reported among 154 canine
isolates in South Africa (Eliasi et al., 2020) appears high compared with data from other continents
(Figure 10), but this is impossible to conclude with no separate information on the intermediate category.
Accordingly, available fluoroquinolone susceptibility data should be interpreted with caution.
Susceptibility data for gentamicin should also be carefully evaluated, as one study (Mekic et al.,
2011) reported 41.3% of isolates with intermediate resistance to that drug. As for fluoroquinolones,
this hampers the comparison of the studies marked in red (%R + I) and blue (%R) in Figure 8.
The lowest level of resistance was reported for polymyxin B with five out of six studies reporting
less than 10% resistance. Interestingly, two studies from Brazil reported 0% and 54.4% resistance in
canine isolates, respectively (Penna et al., 2011; Arais et al., 2016). The reason for this discrepancy is
unknown, as both studies appeared to use the same methods and interpretive criteria, and they both
included dogs from the same geographical area (Rio de Janeiro).
Mixed: isolates recovered from multiple sites reported together; SSTI: skin and soft tissue infections.
Figure 7: Distribution of P. aeruginosa isolates per animal species and site of infection
Total number of studies by continent and antimicrobial is reported on the right side. Each circle represents one
study and the size of each circle reflects how many isolates were included in the study. The colour of a circle
illustrates whether the proportion represents resistance only (red circle) or resistance merged with intermediate
(blue circle). The dashed lines indicate, for each antibiotic, the weighted arithmetic mean of %R (red line) or %R+I
(blue dashed line). The exact percentages these lines represent are listed in Appendix E.
Figure 8: Pseudomonas aeruginosa resistance data for each included study sorted by continent
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3.1.3.4. Staphylococcus aureus and Staphylococcus schleiferi
Staphylococcus aureus and S. schleiferi can reside in the skin and mucous membranes of dogs and
cats, and they mostly cause infections associated with the integumentary system. S. schleiferi
comprises two subspecies, namely the coagulase-negative S. schleiferi subsp. schleiferi and the
coagulase-positive S. schleiferi subsp. coagulans. They both occur in dogs and cats, although probably
more commonly in dogs. S. aureus is more common in humans than in pets; hence, pets are likely to
become colonised through contact with humans. This is particularly clear when studying methicillin-
resistant S. aureus (MRSA), as the MRSA variants most commonly detected in pets (e.g. ST22) are
recognised human-adapted MRSA types. While S. pseudintermedius is very predominant in dogs, S.
aureus appears to be distributed more equally between cats and dogs.
In total, 14 and 4 studies with ≥ 10 S. aureus and S. schleiferi isolates, respectively, and results for
one or more of the relevant antibiotics (clindamycin/lincomycin, enrofloxacin/ciprofloxacin, gentamicin,
doxycycline/tetracycline, methicillin/methicillin-resistance surrogates, sulfonamide-TMP) were included.
Among these studies, 1, 2, 11, 1, 3 and 0 included isolates from Africa, Asia, Europe, Oceania, North
America and South America, respectively.
The distribution of S. aureus and S. schleiferi per animal species and site of infection is depicted in
Figure 9. The vast majority of isolates originated from dogs, and most susceptibility data were
reported for a mixture of infections.
Table 5: Weighted arithmetic average, minimum and maximum proportion of resistance (%R or %R + I)






















Fluoroquinolones Africa 1 154 73 73 73 NA
Fluoroquinolones Asia 5 426 17.7 9 35.4 10.1
Fluoroquinolones Europe 7 2,651 56.4 8 67.7 22.1
Fluoroquinolones North
America
1 1,585 68.5 68.5 68.5 NA
Fluoroquinolones Oceania 1 1,227 36 36 36 NA
Fluoroquinolones South
America
3 292 51.4 26 80 19.4
Gentamicin Africa 1 154 18 18 18 NA
Gentamicin Asia 4 380 9.7 4.1 26.3 9
Gentamicin Europe 9 3,085 16.6 2 56.5 9.2
Gentamicin North
America
1 1,585 17.7 17.7 17.7 NA
Gentamicin Oceania 1 1,206 5 5 5 NA
Gentamicin South
America
3 292 44.6 4.8 71.4 31.6
Polymyxin
B/Colistin
Asia 1 80 3.8 3.8 3.8 NA
Polymyxin
B/Colistin
Europe 2 471 0.8 0 1 0.4
Polymyxin
B/Colistin





2 271 33.5 0 54.4 26.5
NA: Standard deviation cannot be calculated because only one study is included.
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Figure 10 shows for each continent the proportion of resistance reported in individual studies with
at least 10 S. aureus isolates, whereas average values for both S. aureus and S. schleiferi are shown
in Table 7. Information on the proportion of resistance sorted by country is given in Appendix D. Most
data are available from studies in Europe with only sporadic studies from other continents. MR varied
from 0% to 36.4% with the lowest proportion of resistance occurring among 23 canine respiratory
isolates from different countries in Europe (Moyaert et al., 2019) and the highest among 33 cat
isolates from the USA (Lane et al., 2018). An almost equally high MR level (35.9%) was detected in an
Italian study of 39 canine isolates (Ghidini et al., 2011). This study is noteworthy because very high
levels of resistance were observed for clindamycin (100%), enrofloxacin (51.3%), fusidic acid (74.4%),
gentamicin (74.4%) and sulfonamide-TMP (89.7%). One potential reason for this was that it reported
%R + I, unlike most other studies, which reported %R. Another explanation might be that the dogs in
that study had been referred to a veterinary teaching hospital; hence, they had most likely undergone
antimicrobial treatment prior to sampling. It should be mentioned that this was not necessarily specific
to this single study, as veterinary specimens are often submitted to diagnostic labs only after failure of
empirical antimicrobial treatment.
Susceptibility data for S. schleiferi were available from only four studies. Most remarkably,
resistance levels were exceptionally low in Sweden (Swedres-Svarm, 2019) with 0–6% resistance
reported for the six antibiotics tested in 240 isolates. This low resistance was reported despite
reporting %R + I rather than %R. Two American studies found MR in 57.3% and 67.3% of the 225
and 217 isolates they included, respectively (Cain et al., 2011; Kunder et al., 2015).
Mixed: isolates recovered from multiple sites reported together; SSTI: skin and soft tissue infections.
Figure 9: Distribution of S. aureus and S. schleiferi isolates per animal species and site of infection
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Total number of studies by continent and antimicrobial is reported on the right side. Each circle represents one
study and the size of each circle reflects how many isolates were included in the study. The colour of a circle
illustrates whether the proportion represents resistance only (red circle) or resistance merged with intermediate
(blue circle). The dashed lines indicate, for each antibiotic, the weighted arithmetic mean of %R (red line) or %
R + I (blue dashed line). The exact percentages these lines represent are listed in Appendix E.
Figure 10: Staphylococcus aureus and Staphylococcus schleiferi resistance data for each included
study sorted by continent
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Table 6: Weighted arithmetic mean, minimum and maximum proportion of resistance (%R or %R + I)



























S. aureus Fluoroquinolones Africa 1 36 2.8 2.8 2.8 NA
Fluoroquinolones Asia 1 34 2.9 2.9 2.9 NA
Fluoroquinolones Europe 9 959 14.3 0 51.3 9.7
Fluoroquinolones Oceania 1 64 9.4 9.4 9.4 NA
Fusidic acid Europe 3 556 11.6 5 74.4 17.5
Gentamicin Africa 1 36 11.1 11.1 11.1 NA
Gentamicin Asia 1 34 35.3 35.3 35.3 NA
Gentamicin Europe 8 1,013 12.7 0 74.4 14.3
Lincosamides Africa 1 36 55.6 55.6 55.6 NA
Lincosamides Europe 4 655 25.2 4.4 100 19.7
Lincosamides Oceania 1 64 1.5 1.5 1.5 NA
Methicillin Europe 9 983 17.5 0 35.9 8.4
Methicillin North
America
1 33 36.4 36.4 36.4 NA
Methicillin Oceania 1 64 14.1 14.1 14.1 NA
Sulfa/TMP Africa 1 36 25 25 25 NA
Sulfa/TMP Europe 9 980 13.8 0 100 18.3
Sulfa/TMP Oceania 1 64 4.7 4.7 4.7 NA
Tetracyclines Africa 1 36 27.8 27.8 27.8 NA
Tetracyclines Asia 1 34 38.2 38.2 38.2 NA
Tetracyclines Europe 6 584 25.9 10 60 6.1
Tetracyclines Oceania 1 64 9.4 9.4 9.4 NA
S. schleiferi Fluoroquinolones Europe 1 240 3 3 3 NA
Fluoroquinolones North
America
2 442 49.1 45.8 52.5 3.4
Fusidic acid Europe 1 240 6 6 6 NA
Gentamicin Europe 1 240 0 0 0 NA
Gentamicin North
America
2 442 48.1 47.2 49 0.9
Lincosamides Asia 1 20 10 10 10 NA
Lincosamides Europe 1 240 4 4 4 NA
Lincosamides North
America
2 442 25.2 24.9 25.5 0.3
Methicillin Asia 1 20 30 30 30 NA
Methicillin Europe 1 240 0 0 0 NA
Methicillin North
America
2 442 62.2 57.3 67.3 5
Sulfa/TMP Europe 1 240 1 1 1 NA
Sulfa/TMP North
America
2 442 5.8 0.9 10.8 5
Tetracyclines Europe 1 240 3 3 3 NA
Tetracyclines North
America
1 217 19 19 19 NA
NA: Standard deviation cannot be calculated because only one study is included.
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3.1.3.5. Proteus mirabilis, Klebsiella spp. and Enterobacter spp.
Proteus mirabilis, Klebsiella spp. and Enterobacter spp. are opportunistic pathogens residing in the
intestinal tract. Although they occur with lower frequency than E. coli, they are generally capable of
causing the same types of infection in dogs and cats. For example, one study showed that each of
these species accounts for less than 10% of UTIs in dogs (Lin et al., 2012). This overlap with E. coli
also means that the treatment recommendations for infections caused by these bacteria are the same
as for E. coli. Proteus mirabilis is special in the sense that it is among the most common aetiological
agents isolated from otitis externa in dogs. However, Proteus ear infections in dogs are rarely treated
with systemic antibiotics, hence no additional antibiotics for this infection type will be considered here.
In total, only 2, 7 and 10 studies with ≥ 10 Enterobacter spp., Klebsiella spp. and Proteus mirabilis
isolates, respectively, and results for one or more of the relevant antibiotics (ampicillin/amoxicillin,
enrofloxacin/ciprofloxacin, nitrofurantoin, sulfonamide–trimethoprim, 3GCs) were included. Among
these studies, 0, 6, 10, 1, 0 and 0 included isolates from Africa, Asia, Europe, Oceania, North America
and South America, respectively.
The distribution of Klebsiella spp., Enterobacter spp. and P. mirabilis isolates per animal species and
site of infection is depicted in Figure 11. The vast majority of isolates originated from dogs, and most
susceptibility data were reported for a mixture of infections. The reason for that is probably a shortage
of isolates in diagnostic laboratories; hence it would not make sense to report few isolates for a single
infection type separately.
Figure 12 shows, for each continent, the proportion of resistance reported in individual studies with
at least 10 Proteus mirabilis, Klebsiella spp. and Enterobacter spp. isolates, whereas average values
are shown in Table 5. Information on proportion of resistance sorted by country is given in
Appendix D. The data set should be interpreted with care due to the few studies per continent.
Mixed: isolates recovered from multiple sites reported together; SSTI: skin and soft tissue infections.
Figure 11: Distribution of Klebsiella spp., Enterobacter spp. and P. mirabilis isolates per animal
species and site of infection
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For Proteus mirabilis the highest levels of resistance to sulfonamide–TMP (87.5%), 3GC (75.0%)
and amoxicillin–clavulanic acid (87.5%) were reported from an Italian study by Rampacci et al. (2018),
but this was based on only 16 isolates.
For Klebsiella spp. (K. pneumoniae and K. oxytoca), the most remarkable finding was in a hospital
outbreak study from France (Haenni et al., 2012) reporting 100% of 24 K. pneumoniae isolates being
resistant to both 3GCs and fluoroquinolones. Typing a subset of those isolates showed that they were
genetically indistinguishable, belonging to ST15 and harbouring blaCTX-M-15. This emphasises the
challenge of including data from studies representing very few – or even a single – study unit such as
a hospital. Data per continent is displayed in Figure 12 and Table 7.
One of the two studies on Enterobacter spp. (E. cloacae) showed that 3.5% and 10.2% of 314 dog
and 108 cat isolates, respectively, in France were resistant to 3GCs, and all isolates were confirmed by PCR
to harbour an ESBL gene (Haenni et al., 2016). The other study showed that 33.3% and 43.3% of
Enterobacter spp. isolates were resistant to 3GC and ciprofloxacin, respectively (Harada et al., 2017).
Total number of studies by continent and antimicrobial is reported on the right side. Each circle represents one
study and the size of each circle reflects how many isolates were included in the study. The colour of a circle
illustrates whether the proportion represents resistance only (red circle) or resistance merged with intermediate
(blue circle). The dashed lines indicate, for each antibiotic, the weighted arithmetic mean of %R (red dashed
line) or %R + I (blue dashed line). The exact percentages these lines represent are listed in Appendix E.
Figure 12: Proteus spp. and Klebsiella spp. resistance data for each included study sorted by continent
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3.1.3.6. Enterococcus faecalis and Enterococcus faecium
Enterococci are found in the intestinal tract of animals and humans and regarded as opportunistic
pathogens. They may cause a variety of diseases, but in pets are typically associated with ear
infections and UTIs. Care should be taken when assessing growth of enterococci, as they often occur
as contaminants in mixed cultures.
No eligible studies were found for E. faecium, whereas one American and one Swedish study (on E.
faecalis and Enterococcus spp., respectively) reported more than 50% resistance to enrofloxacin and
less than 20% resistance to ampicillin (Windahl et al., 2014; KuKanich and Lubbers, 2015). A third
study (Rampacci et al., 2018) reported that almost all 39 tested E. faecalis isolates were resistant to
sulfonamide-TMP (Figure 13). This is an expected result, as enterococci are known to be intrinsically
resistant to folic acid synthesis inhibitors.
Table 7: Weighted arithmetic mean, minimum and maximum proportion of resistance (%R or %R +
I) and weighted standard deviation in Proteus, Enterobacter spp. and Klebsiella spp. for


























3GC Asia 2 138 10.8 1.9 37 15.3
3GC Europe 4 1,165 4 1.8 75 8.6
Aminopenicillins Asia 2 138 24.5 8.7 71 27.2
Aminopenicillins Europe 3 1,144 27.9 9.1 28.9 4.2
Amox/Clav Europe 6 1,581 11.3 3.9 68.7 6.4
Amox/Clav Oceania 1 356 3.7 3.7 3.7 NA
Fluoroquinolones Asia 1 103 12.6 12.6 12.6 NA
Fluoroquinolones Europe 5 2,464 10.8 3.6 26.2 5
Fluoroquinolones Oceania 1 357 0.3 0.3 0.3 NA
Nitrofurantoin Europe 1 55 90.9 90.9 90.9 NA
Sulfa/TMP Asia 2 138 25.5 10.7 69 25.5
Sulfa/TMP Europe 7 2,595 23.2 10.9 87.5 6.8
Sulfa/TMP Oceania 1 356 5.3 5.3 5.3 NA
Enterobac-
ter spp.
3GC Asia 1 60 33.3 33.3 33.3 NA
3GC Europe 1 422 5.2 5.2 5.2 NA
Aminopenicillins Asia 1 60 93.3 93.3 93.3 NA
Amox/Clav Asia 1 60 93.3 93.3 93.3 NA
Fluoroquinolones Asia 1 60 43.3 43.3 43.3 NA
Klebsiella
spp.
3GC Asia 3 80 42.6 12.5 53 15.4
3GC Europe 4 892 14.9 0 100 21.6
Aminopenicillins Asia 2 50 81.9 62.5 91 13.4
Aminopenicillins Europe 1 11 100 100 100 NA
Amox/Clav Asia 2 50 30.3 21 50 13.7
Amox/Clav Europe 2 47 76.6 27.3 91.7 27.6
Fluoroquinolones Asia 2 50 25.8 12.5 32 9.2
Fluoroquinolones Europe 2 35 71.4 9.1 100 42.8
Nitrofurantoin Europe 1 11 72.7 72.7 72.7 NA
Sulfa/TMP Asia 1 34 53 53 53 NA
Sulfa/TMP Europe 2 47 72.4 9.1 91.7 35.4
NA: Standard deviation cannot be calculated due to only one study being included.
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3.1.3.7. Bordetella bronchiseptica
Bordetella bronchiseptica is a respiratory pathogen capable of causing upper and lower respiratory
infections in dogs and cats. The organism appears more likely to cause infection in stressful or
crowded conditions, e.g. when animals are housed in shelters or kennels.
Only one eligible study (Rheinwald et al., 2015) reported susceptibility data for B. bronchiseptica.
The study showed that all 23 tested isolates were susceptible to doxycycline, which is generally the
preferred drug for respiratory infections caused by this pathogen. Further, 0%, 8.7% and 61.5% of
isolates were resistant to enrofloxacin, amoxicillin– clavulanic acid and ampicillin, respectively. It should
be noted that the study was close to being considered ineligible, as it referred to ‘current CLSI
guidelines’ without specifying the actual document(s) used to standardise the method and
interpretation of susceptibility testing.
3.1.3.8. Clostridium perfringens and Clostridioides difficile
The role of clostridia (C. perfringens and C. difficile) in gastrointestinal infections of dogs and cats is
uncertain, as the bacteria may be found in both healthy and diseased animals (e.g. up to 80%
intestinal carriage is reported in both healthy and diarrhoeic dogs). Toxigenic strains, more commonly
found in diarrhoeic than in healthy animals, may have a potential role as pathogens.
No eligible studies reported resistance in C. difficile, whereas a single study reported resistance in
C. perfringens isolated from dogs with diarrhoea (Gobeli et al., 2012). In that study, none of the 50
isolates tested (with various combinations of toxins) displayed resistance to the clinically relevant
antibiotics ampicillin and metronidazole. It should be noted that the dogs all originated from the same
veterinary practice in Switzerland, and there are no veterinary breakpoints for this anaerobic
bacterium; hence, data should be interpreted carefully and not extrapolated to other geographical
areas.
3.1.4. Assessment of data from national AMR surveillance reports
Seven national AMR reports (DANMAP – Denmark, NORMVET – Norway, FINRES – Finland,
SWEDRES-Svarm – Sweden, RESAPATH – France, ANRESIS/ARCH-Vet – Switzerland and GERM-Vet –
Germany) reporting relevant data on antimicrobial resistance in one or more of the pathogens of
interest in this opinion were also included in the literature review. Data from the latest reports
published at the time the ELR were conducted are included in Appendix B and were used to describe
the global state of play in the previous sections. Additional detail on the information available in each
report, with a focus on historic data (up to the previous five years), and the differences/similarities
with the results presented in Section 3.1.3 follows. Data provided in all reports except one were
obtained from isolates that were either directly isolated and tested for resistance in a specific
laboratory that received the clinical samples, or to which isolates were submitted from other
laboratories for AST. In the remaining report (RESAPATH), AST results submitted to 71 laboratories (in
2018) were presented together. Assessment of changes in AMR over time in the pathogens under
evaluation based on the data in the reports is hampered in certain cases by the lack of consistent
reporting over the years (i.e. only data from specific years were reported) and/or because data on
isolates retrieved over several years were presented together. Furthermore, between-country
Total number of studies by continent and antimicrobial is reported on the right side. Each circle represents one
study and the size of each circle reflects how many isolates were included in the study. The colour of a circle
illustrates whether the proportion represents resistance only (red circle) or resistance merged with intermediate
(blue circle). The dashed lines indicate, for each antibiotic, the weighted arithmetic mean of %R (red line) or
%R + I (blue dashed line). The exact percentages these lines represent are listed in Appendix E.
Figure 13: Enterococcus spp. resistance data for each included study sorted by continent
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comparisons must be performed carefully, since different methodologies are applied to obtain the
results presented in each report, and results provided here are those provided in the reports (e.g.
without accounting for the use of different breakpoints). A comparison of the methodology, bacterial
pathogens, number of isolates and temporal coverage of the information provided in the last five
reports of each monitoring programme is provided below (Table 8), and additional details on each
programme follow.
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Table 8: AMR methodology, bacterial species, host species, number of isolates and temporal coverage of the information on pathogens of interest from
cats and dogs provided in the seven national AMR surveillance reports (up to the last five) reviewed in this opinion
Programme DANMAP NORMVET FINRES SWEDRES-Svarm RESAPATH ANRESIS GERM-Vet
Country Denmark Norway Finland Sweden France Switzerland Germany
Laboratory method Broth microdilution Broth microdilution Disk diffusion Broth microdilution Disk diffusion Broth microdilution Broth microdilution
AST interpretation Clinical breakpoints ECOFFs Clinical breakpoints ECOFFs ECOFFs Clinical breakpoints Clinical breakpoints
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Programme DANMAP NORMVET FINRES SWEDRES-Svarm RESAPATH ANRESIS GERM-Vet






AST: antimicrobial susceptibility testing; ECOFF: epidemiological cut-off.
(a): Among those reported in the last five published reports.
(b): Number of isolates provided stratified by clinical specimen.
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3.1.4.1. DANMAP (Denmark)
Since there is no systematic surveillance system for AMR in cats and dogs, data included in the
report (DANMAP, 2019) came from a study conducted using 1,177 E. coli and 1,763 S.
pseudintermedius isolates from cat and dog clinical samples submitted in 2011–2012 and 2016–2019
to the Veterinary Diagnostic Microbiology Laboratory at the University of Copenhagen, which receives
samples from the whole country. Resistance data were generated using broth microdilution methods
and interpreted according to veterinary CLSI clinical breakpoints. Two periods (before/after 2012) were
considered to assess the potential impact of the release of the national guidelines for antimicrobial
treatment of companion animals (launched in late 2012), and resistance data are provided separately
for isolates from 2011–2012, 2016–2017 and 2018–2019 (with 2018–2019 being included in
Appendix B).
When considering the evolution of resistance, no major overall fluctuations over time were found:
for S. pseudintermedius similar values in the proportion of resistant isolates were obtained in all
sampling periods for which data were available for fluoroquinolones (2–3% resistance depending on
the year), gentamicin (2–3%), lincosamides (25–28%), oxacillin (surrogate for MR) (6–8%),
sulfonamide-TMP(5–6%) and tetracyclines (29–33%). These values were similar to the weighted
arithmetic means provided for these antimicrobials in Table 3 for European countries, except for
fluoroquinolones and aminoglycosides; lower values were found in Danish isolates, although this is not
surprising given the high dispersion of results from European countries as expressed by the large
weighted standard deviations for these antimicrobial classes (Table 3).
Similarly, in the case of E. coli, no clear trends in the percentage of resistant isolates in all sampling
periods were reported for 3GC (4–7% resistance depending on the year), aminopenicillins (with a
larger change over the periods considered, 14–28%), amoxicillin/clavulanic acid (4–9%) and
fluoroquinolones (3–8%), while a decrease from 15% in 2011–2012 to 7–9% in 2016–2017 and 2018–
2019 for sulfonamide-TMP was found. This decrease was attributed to the withdrawal of the only
sulfonamide-TMP product licensed for dogs and cats in 2014. Compared with the weighted arithmetic
means for isolates in Europe presented in Table 4, values recorded in clinical E. coli included in the
DANMAP report were close for all antimicrobials except amoxicillin/clavulanic acid, for which lower
values were found.
3.1.4.2. NORMVET (Norway)
Isolates subjected to AST from dogs included in the NORMVET report (Norm/Norm-Vet, 2019) were
retrieved from clinical submissions sent to the Norwegian Veterinary Institute and included S.
pseudintermedius and E. coli. Resistance data were generated using broth microdilution, and results
were interpreted according to the ECOFFs recommended by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST). Although isolates were retrieved over several years (2017 and 2018
for S. pseudintermedius, 2016– 2018 for E. coli), sample size was reduced (89 E. coli isolates from
UTIs and 43 from other infections, 157 S. pseudintermedius isolates) and the proportion of resistant
isolates is provided grouped; therefore, it is not possible or feasible to assess the existence of changes
over time, since, in addition, previous reports have not included data on isolates from cats and dogs.
For S. pseudintermedius, the proportion of resistant isolates found was below (fluoroquinolones:
1.3%; gentamicin: 1.9%; lincosamides: 12.7%; presence of mecA gene (conferring MR): 4.4%) or
close to the weighted arithmetic mean provided in Table 3 (tetracyclines: 26.8%), except for fusidic
acid providing the maximum value (38.2%) registered for this antimicrobial in a European country.
In the case of E. coli, resistance levels in isolates retrieved from UTIs were lower than in isolates
from other infections for the three antimicrobials included in the ELR in the report. With the weighted
arithmetic mean found for E. coli, resistance levels in isolates retrieved from UTIs were lower than in
isolates from other infections for the three target antimicrobials included in this opinion (3GC: 0 vs
7.0%; aminopenicillins: 20.2 vs 46.5%; fluoroquinolones: 4.5 vs 16.3%). The weighted arithmetic
mean found for E. coli isolates from Europe presented in Table 4 falls between both estimates for the
three antimicrobials.
3.1.4.3. FINRES (Finland)
Data on AMR from clinical isolates retrieved from cats and dogs reported in this national report
(FINRES-Vet, 2019) originated from isolates submitted to the Clinical Microbiology Laboratory of the
Faculty of Veterinary Medicine of the University of Helsinki, which receives isolates from both the
Veterinary Teaching Hospital of the University (~36% of specimens) and private veterinary clinics
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(~ 64%). Resistance was tested using the disk diffusion technique and results were interpreted using
(when available, veterinary) CLSI clinical breakpoints. Results of AST on clinical S. pseudintermedius,
E. coli and P. aeruginosa starting after 2014 (2015 for certain antimicrobials) are provided in the
reports, allowing for an assessment of changes in the proportion of resistance over time. Yearly data
(exact proportion of resistant isolates) were kindly provided by Thomas Gr€onthal (University of
Helsinki, Faculty of Veterinary Medicine) for this scientific opinion.
For S. pseudintermedius, information on all seven antimicrobial classes of interest was available on
isolates retrieved from dog samples (Figure 14), with between 396 and 936 isolates tested per year.
The proportion of resistance in clinical isolates varied, largely depending on the antimicrobial, but in
general decreasing (tetracyclines, lincosamides, fusidic acid, methicillin, gentamicin and enrofloxacin)
or stable (sulfonamides-TMP) levels were observed in the most recent years compared with the
earliest. Levels of resistance were in line with the weighted arithmetic means provided in Table 3,
except for fluoroquinolones and gentamicin (lower values) and fusidic acid (higher values), although
reported values were well within 1–2 standard deviations from the weighted means (Table 3).
For E. coli, results are presented separately for cat (50–211 isolates/year reported) and dog
(310–1,041 isolates/year reported) clinical isolates. The proportion of resistance followed a similar
pattern in isolates from both host species (e.g. higher resistance levels to aminopenicillins followed by
amoxicillin–clavulanic acid combinations) in line with data from European studies reported in Table 4,
although lower levels in the majority of the antimicrobials were reported in isolates from cats
(Figure 15). In terms of changes in resistance over time, lower resistance levels were observed in
more recent years for amoxicillin–clavulanic acid, 3GC and fluoroquinolones in canine isolates, while
values fluctuated without a clear trend for the remaining antimicrobials. Values observed were in line
with the weighted arithmetic means calculated from European studies for most antimicrobials except
for aminopenicillins, for which higher values were observed (Table 4).
CLI: clindamycin; DOX: doxycycline; ENR: enrofloxacin; FUS: fusidic acid; GEN: gentamicin; OXA: oxacillin; SXT:
sulfonamides-TMP.
Figure 14: Proportion of resistance in clinical S. pseudintermedius from dogs reported in the FINRES
report
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Finally, data on resistance to the three antimicrobials of interest for P. aeruginosa (enrofloxacin,
gentamicin and polymyxin B) were provided for 105 canine isolates tested in 2018: resistance levels
provided for each antimicrobial were similar (polymyxin B = 0%) or lower (gentamicin = 4%;
enrofloxacin = 18%) than weighted arithmetic means provided for European studies in Table 6,
although this should be interpreted carefully given the limited number of isolates (and the difficulties
with interpreting fluoroquinolone susceptibility data for this bacteria already mentioned in
Section 3.1.3.4).
3.1.4.4. SWEDRES-Svarm (Sweden)
Reports from the SWEDRES report (Swedres-Svarm, 2019) include data on resistance from clinical
isolates retrieved from clinical samples from cats and dogs primarily performed at the National
Veterinary Institute. These data have been included for more than 15 years, although the bacterial
species analysed and the origin of the isolates (i.e. type of clinical specimen) have been modified over
time. If the last five reports are considered (those published between 2014 and 2019, reporting data
on isolates cultured the previous year), data on several antimicrobials of interest for this scientific
opinion are reported for S. pseudintermedius, S. schleiferi and P. aeruginosa from dogs, and E. coli
from both dogs and cats. Isolates were analysed using the broth microdilution method, and results
were interpreted according to the ECOFFs recommended by EUCAST.
For S. pseudintermedius, data on resistance to fluoroquinolones (enrofloxacin), fusidic acid,
gentamicin, lincosamides (clindamycin), oxacillin (surrogate for MR), sulfonamides-TMP and tetracycline
in isolates retrieved from skin samples have been included in the five annual reports considered
(although enrofloxacin was not included in 2015). The number of isolates tested every year ranged
AMC: amoxicillin–clavulanic acid; AMP: ampicillin; CPD: cefpodoxime; ENR: enrofloxacin; SXT: sulfonamides-TMP.
Figure 15: Proportion of resistance in clinical E. coli from dogs and cats reported in the FINRES
report
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between 376 and 784), and showed stable levels of resistance for most antimicrobials, which were
consistently higher (> 15–20%) for tetracyclines and fusidic acid than for enrofloxacin, gentamicin and
oxacillin (< 5%), while data for clindamycin and sulfonamides-TMP were much more variable (with a
decreasing trend in the last two years) (Figure 16). Resistance levels reported in the annual reports
were relatively similar to the weighted arithmetic means for clinical isolates from Europe reported in
Table 3 for tetracyclines and sulfonamides-TMP, lower for fluoroquinolones, methicillin, gentamicin and
clindamycin (particularly for values observed after 2016), and higher in the case of fusidic acid.
In the reports published in 2018 and 2019, additional resistance data are provided for
S. pseudintermedius retrieved in the previous year from samples from the external ear canal and from
wounds (with 415–517 and 844–1005 isolates tested each year, respectively). Resistance levels are
more or less consistent across origins (i.e. higher resistance levels are observed for tetracyclines,
fusidic acid, clindamycin and sulfonamides-TMP, regardless of the specimen from which isolates were
cultured) but certain differences can be observed in the two years for which data are available from all
three sites (e.g. higher levels of clindamycin resistance for samples from the external ear canal)
(Figure 17).
Figure 16: Proportion of resistance in clinical S. pseudintermedius from skin samples from dogs
reported in the SWEDRES-Svarm report
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For E. coli, resistance data to cefotaxime, ampicillin, enrofloxacin, nitrofurantoin and sulfonamides-
TMP in isolates from urine samples from cats (between 455 and 545 isolates/year) and dogs (943–
1,162 isolates/year) was provided in the five reports reviewed. Resistance levels in isolates from cats
and dogs were relatively similar for ampicillin (> 12%), and cefotaxime and nitrofurantoin (≤ 2%). For
the remaining two antimicrobials, opposite trends were observed, with dog isolates showing lower
levels of resistance (and a decreasing trend over the five years) to enrofloxacin and higher levels to
sulfonamides-TMP (Figure 18).
Figure 17: Proportion of resistance in clinical S. pseudintermedius retrieved in 2017 and 2018 from
different specimens from dogs as reported in the SWEDRES-Svarm report
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When compared with the weighted arithmetic mean of resistance estimated from European studies
for E. coli (Table 4), resistance levels were lower for ampicillin, cefotaxime and sulfonamides-TMP, and
similar for nitrofurantoin (for which only one other study in addition to the SWEDRES-Svarm report
provided data) and enrofloxacin (lower if considering dog isolates).
Regarding resistance in P. aeruginosa, between 306 and 389 isolates retrieved from clinical dog
samples collected from the external ear canal were tested for resistance to colistin, gentamicin and
enrofloxacin between 2014 and 2018. Levels of resistance were low (≤ 2%) for the two-first
antimicrobials, while enrofloxacin resistance levels ranged between 8 and 13% (with a decreasing
trend in the most recent years) (Figure 19).
Figure 18: Proportion of resistance in clinical E. coli retrieved from clinical samples from various
locations from cats and dogs reported in the SWEDRES-Svarm report
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Finally, for S. schleiferi, between 163 and 297 isolates from clinical submissions from various locations
(primarily from the external ear canal, skin and wounds) were tested every year between 2014 and 2018.
As reported in Section 3.1.3.4, levels of resistance were low for all seven antimicrobials tested by the end
of this period, although somewhat higher levels of resistance were found in 2016 for most antimicrobials
(Figure 20). Values for the last year are in agreement with those presented in Table 7 for Europe because
in fact this is the study that was used to provide those values.
Figure 19: Proportion of resistance in clinical P. aeruginosa from clinical samples from the external
ear canal of dogs reported in the SWEDRES-Svarm report
Figure 20: Proportion of resistance in clinical S. schleiferi from clinical samples from various locations
of dogs reported in the SWEDRES-Svarm report
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3.1.4.5. RESAPATH (France)
The RESAPATH reports (Resapath, 2021) provide resistance data on clinical isolates from cats and
dogs belonging to several bacterial species and antimicrobials of interest, generated at laboratories
that are part of the French surveillance network for AMR in bacteria from diseased animals. Resistance
is determined according to the disk diffusion method (AFNOR NF U47-107 standard), and results are
interpreted according to the veterinary guidelines of the Antibiogram Committee of the French Society
of Microbiology (CA-SFM). When considering the last five years, resistance data for E. coli were
available from cats and dogs (2014–2018), P. mirabilis from dogs (2015–2018) and S.
pseudintermedius and S. aureus from dogs (2017–2018). Because data are generated in various
laboratories, the number of isolates from each bacterial species tested each year varies and isolates
are not always tested against the same panel of antimicrobials.
When considering S. pseudintermedius, data on resistance to all seven antimicrobials/antimicrobial
classes of interest were available from clinical isolates retrieved in 2017 and 2018 for three different
clinical presentations (kidney and urinary tract pathology, otitis, SSTI) although in very variable
numbers: while the number of isolates from otitis tested for any antimicrobials was the largest
(between 807 and 1,138), results for isolates from skin and soft tissue infections (between 529 and
800 isolates tested for any of the selected antimicrobials) and kidney and urinary tract (between 198
and 311 isolates tested for any of the selected antimicrobials except fusidic acid, with only 30 strains
tested in 2017) were more limited. Nevertheless, similar patterns irrespective of the type of clinical
presentation were observed, with higher resistance levels for tetracyclines (> 35%) and lincosamides
(lincomycin, ≥ 30%), although somewhat higher levels of resistance were observed for isolates from
SSTIs for several antimicrobials (Figure 20). When comparing these results with the weighted
arithmetic means for Europe reported in Table 3, they are similar for fluoroquinolones, gentamicin,
lincosamides, methicillin (except for samples from SSTIs, with higher resistance levels according to the
French data), and sulfonamides-TMP, higher for tetracyclines, and lower for fusidic acid. If these
results are compared with the S. pseudintermedius data provided in the SWEDRES-Svarm reports for
the same years, values are consistently higher for all antimicrobials and locations, although
comparisons must be interpreted carefully due to possible differences in the AST methodologies and
interpretative criteria (Table 6).
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For E. coli, resistance data from isolates from both cats and dogs are reported for the five years
considered, though sampling site is only specified in the case of canine strains. Again, numbers of
isolates tested each year for each antimicrobial varies, with larger sample sizes in general in the most
recent years, and overall numbers ranging from 488 to 1,539 for kidney and urinary tract samples, 73
to 277 for otitis and 41 to 153 for SSTIs (all from dogs), and from 322 to 1,351 from cats (all
pathologies reported together). Levels of resistance to each antimicrobial are relatively stable over
time albeit with lower levels for most antimicrobials in the most recent years (Figure 21). Higher levels
of resistance to amoxicillin and amoxicillin–clavulanic acid for all categories followed by sulfonamides-
TMP and then ceftiofur and enrofloxacin. Similar to what was reported for S. pseudintermedius,
somewhat higher levels of resistance were reported for E. coli canine isolates from SSTIs, although
this should be interpreted with care, particularly given the limited sample size for this specific category.
Values reported in the RESAPATH reports were close to the weighted arithmetic means reported in
Table 4 for European isolates for 3GC, aminopenicillins (except for isolates from SSTIs, in which higher
levels of resistance were reported) and sulfonamides-TMP (particularly when considering the later
years), and somewhat higher (especially for the SSTI isolates) for amoxicillin–clavulanic acid, while
lower values (particularly for the later years) were reported for fluoroquinolones.
SSTI: skin and soft tissue infections.
Figure 21: Proportions of resistant canine S. pseudintermedius isolates cultured from different clinical
samples in 2017 and 2018 reported in RESAPATH reports
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For S. aureus, resistance data for between 246 and 488 canine isolates tested against one of the
seven antimicrobials of interest were provided for 2017 and 2018 with the exception of fusidic acid in
2018, for which only 30 isolates were tested. Relatively similar levels were found for all antimicrobials
except for fusidic acid, which was tested in a very small sample size (Figure 23). Resistance levels to
tetracycline and lincomycin were higher (> 20%) than those found in all other antimicrobials, which
were around or below 10%. Values reported in RESAPATH were similar to the weighted arithmetic
means for Europe provided in Table 7 for all antimicrobials except for oxacillin, where lower levels of
resistance were found for the French isolates.
SSTI: skin and soft tissue infections.
Figure 22: Proportions of resistance in E. coli from clinical samples from cats (all pathologies) and
from various locations on dogs reported in the RESAPATH reports
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Finally, for P. mirabilis, data on resistance were provided for canine isolates from different
pathologies reported together and retrieved between 2015 and 2018. The number of isolates tested
against each of four antimicrobials of interest each year was lower in 2015 (between 366 and 384)
and increased in the following three years (between 1,100 and 1,468 isolates for 2016–2018).
Resistance levels in this case were the highest for sulfonamides-TMP (> 20%), although values
recorded each year were decreasing to some extent (Figure 24). Decreasing values in the later years
were also observed for enrofloxacin (from 16% to 7%) and ceftiofur (from 3% to 1%), while
resistance levels for amoxicillin–clavulanic acid ranged between 8% and 11% over the four years
(Figure 24). These values were similar to the weighted arithmetic means provided in Table 5 for
isolates in Europe, except for the latter estimates for 3GC and fluoroquinolones, which were somewhat
lower.
Figure 23: Proportions of resistance in clinical S. aureus retrieved in 2017 and 2018 from all
pathologies from dogs reported in the RESAPATH reports
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3.1.4.6. ANRESIS/ARCH-Vet (Switzerland)
The Swiss AMR report (Anresis, 2020) included data from cats and dogs for the first time in the
report published in 2020 (corresponding to isolates retrieved in 2019), and therefore there is only one
year’s worth of data. Isolates included in the report originate from veterinary diagnostic laboratories in
the country that are submitted to the Swiss national reference laboratory for AMR and are retrieved
from animals not subjected to antimicrobial treatment prior to sampling. Resistance data, generated
using the broth microdilution method and interpreted according to CLSI clinical breakpoints, were
provided for a limited number of S. pseudintermedius isolates from skin infections from dogs (n = 22)
and of E. coli from canine (n = 40) and feline (n = 35) urogenital tract infections.
Resistance levels (R + I) for the antimicrobials of interest tested in 22 canine S. pseudintermedius
isolates were somewhat lower (ciprofloxacin: 0%; gentamicin: 5%) or in the same range (clindamycin:
32%; tetracycline: 23%) compared with weighted arithmetic means calculated for all Europe (Table 3).
In the case of the E. coli isolates, resistance levels were either similar to or below (3GC for dog
isolates, aminopenicillin in both species) the weighted average mean estimates for European studies
presented in Table 4, except for fluoroquinolone in dog isolates (Table 7).
3.1.4.7. GERM-VET (Germany)
Since 2001, the Bundesamt f€ur Verbraucherschutz und Lebensmittelsicherheit (BVL) started to
monitor resistance in animal bacterial pathogens and it reports data in GERM-Vet (Germ-Vet, 2020)
according to a yearly sampling plan, sampled each year from mid-April of the reporting year to the end
of March of the following year. In 2014 and 2015, between 22 and 32 public, private and university
Figure 24: Proportions of resistance in P. mirabilis from clinical samples of dogs (all pathologies)
reported in the RESAPATH reports
Table 9: Proportion of E. coli isolates from canine and feline urogenital tract infections resistant to
selected antimicrobials in 2019
Antimicrobial Dog (n = 40) Cat (n = 35)
3GC (cefotaxime) 0% 6%
Aminopenicillin (ampicillin) 15% 17.1%
Fluoroquinolone (ciprofloxacin) 15% 3%
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laboratories were included. Resistance monitoring was performed according to CLSI guidelines.
Resistance was defined using clinical breakpoints that, however, changed over the years. Among the
bacterial species of interest, resistance data on E. coli and B. bronchiseptica isolates retrieved from
diseased animals identified in the submitting laboratories (a proportion of them rechecked at the BVL
laboratory) have been included in the reports.
Resistance data for E. coli were provided separately for intestinal and UTI isolates. The number of
isolates tested each year was in any case limited, ranging from 59 to 131 (considering both locations
together). Regarding isolates from the gastrointestinal tract, resistance levels to ampicillin and
amoxicillin/clavulanic acid based on clinical breakpoints in canine and feline isolates (reported together)
ranged between 18 and 40% for 2014–2016, while the proportion of resistance to ampicillin and
amoxicillin/clavulanic acid in isolates from cats in the years 2017 and 2018 was defined as 100%.
Resistance rates to fluoroquinolones (determined from UTI isolates) ranged over the years between 0
and 25%. Sulfonamide-TMP resistance decreased from over 15–20% in 2015–2017 to less than 10%
in 2018.
3.2. ToR 2: identifying the most relevant bacteria in the EU
Following the methodology presented in the scientific opinion on the ad hoc method for the
assessment of animal diseases caused by bacteria resistant to antimicrobials within the AHL framework
(EFSA AHAW Panel, 2021), the evidence available was assessed individually by all working group
members who provided individual judgements on the perceived relevance to dogs and cats of the
antimicrobial-resistant bacteria included in the list.
After discussion of the individual judgements for each bacterium (relevant/non-relevant/cannot be
assessed based on available evidence), it was agreed with > 90% certainty that the three most
relevant antimicrobial resistant bacteria for the EU were S. pseudintermedius, E. coli and P. aeruginosa
(Figure 25). This is due to their frequent implication in clinical disease in cats and dogs and the high
levels of resistance to clinically relevant antimicrobials both globally and in some cases also in the EU
(methicillin, lincosamide and fluoroquinolones for S. pseudintermedius (Table 3), aminopenicillin, 3GCs
and fluoroquinolones for E. coli (Table 4) and aminoglycosides and fluoroquinolones for P. aeruginosa
(Table 6). Their potential relevance as antimicrobial resistant pathogens is evidenced by the very large
number of AST results for the antimicrobials of interest retrieved through this ELR for these three
species (~ 121,000 test results for E. coli, ~ 83,000 for S. pseudintermedius and ~ 15,000 for P.
aeruginosa) (Appendix B).
Among the remaining bacteria considered in the ELR but not considered among the most relevant
for the EU, there was a much higher uncertainty regarding their inclusion among the most relevant
antimicrobial resistant pathogens in the EU (Figure 25). For four of them (Klebsiella spp., P. mirabilis, S.
aureus and Enterobacter spp.), there was already sufficient evidence suggesting that resistant strains
can cause clinical problems at present, particularly considering that mechanisms mediating resistance
dynamics (e.g. transmission, persistence) are similar to those of some of the bacteria considered as
most relevant (e.g. the epidemiology of AMR in Enterobacter or Klebsiella can be expected to follow
similar patterns to that of E. coli). Still, there were limited data suggesting that antimicrobial resistant
phenotypes of these bacterial species are a significant concern at this time, especially taking into
consideration their relatively low frequency in clinical specimens from dogs and cats.
The clostridial species included in the assessment (C. perfringens, C. difficile) were not considered
relevant, since treatment of enteritis does not typically pose therapeutic problems. Furthermore, given
that they can be retrieved from both healthy and diseased individuals, the evaluation of their clinical
relevance is contentious.
Finally, for the remaining four species (S. schleiferi, E. faecalis, E. faecium and B. bronchiseptica),
very limited data on AMR were available (four studies testing between 20 and 240 isolates each for S.
schleiferi, three studies with results for 11–55 isolates each for Enterococcus spp., one study with 23
isolates for B. bronchiseptica). Even if the resistance levels found were non-negligible for certain
antimicrobial–pathogen combinations outside Europe (e.g. methicillin and fluoroquinolone resistance in
S. schleiferi in the US), lower levels of resistance were observed in European isolates. Moreover, S.
schleiferi is not a frequent cause of infection in dogs and cats in Europe, B. bronchiseptica appears to
be consistently susceptible to the first-choice drug for treatment of respiratory infections (doxycycline),
and enterococci were not perceived as a major cause of treatment failure, also in view of their role as
secondary pathogens in UTIs, often in combination with E. coli or other primary pathogens that are
the main target of antimicrobial treatment.
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4. Conclusions
In this opinion, EFSA presents the results of the assessment conducted to answer ToR 1 (global
state of play of antimicrobial-resistant animal bacteria) and the first part of ToR 2 (identifying the most
relevant in the EU) as they are described and interpreted in the ad hoc methodology (EFSA AHAW
Panel, 2021). The second part of ToR 2 and ToR 3, namely the animal health impact of the selected
species on swine in the EU, and their eligibility for being listed and categorised in the framework of the
AHL, will be assessed in the next step of this EFSA project.
The scientific assessment of the global state of play of the resistant bacterial pathogens of cats and
dogs included in this opinion and of their EU relevance is hampered by several important sources of
uncertainty derived from the available data and the methodology followed in this assessment, as
mentioned in Section 2.4 of EFSA AHAW Panel (2021) and in the preceding sections of this opinion:
• Due to the scope of the ELR, only studies published in the last 10 years and in English were
considered eligible (with the only exception of the GERMVET report), thus introducing a
selection bias that could lead to the absence of data from several areas of the world where
these resistant pathogens may be highly relevant.
• Information on the rationale and study design for the references retrieved in the ELR was
limited and very heterogeneous, making the detailed assessment of the representativeness of
the isolates included in each study very difficult. For example, approximately half of the
references (46/98) included isolates collected through the regular testing of veterinary
diagnostic laboratories for which typically very limited information is available. Moreover, they
often originate from animals subjected to previous antimicrobial treatments, which has been
demonstrated to be associated with higher levels of resistance in tested isolates. Furthermore,
several of the bacterial species included here can also be found in healthy animals (e.g. E. coli,
S. pseudintermedius). Therefore, even if they originated from diseased animals, they may not
have been the causative agent in a proportion of cases that cannot be quantified.
Figure 25: Level of certainty regarding the inclusion of the selected antimicrobial resistant pathogens
of cats and dogs among the most relevant in the EU
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• Even though only studies exceeding a minimum quality threshold were included (e.g. use of
internationally accepted standards) the methodology used was also diverse (e.g. use of disk
diffusion or microdilution methods, clinical breakpoints or ECOFFs, consideration or not of the
intermediate category, etc.). Thus, descriptive statistics provided here (average proportion of
resistant isolates for bacterium, country and antimicrobial) should be considered carefully, since
they may not be representative of the true underlying situation, particularly in cases where the
sample size was small.
• AMR data referring to one or more of the bacterial pathogens of interest were retrieved from
seven national AMR monitoring reports. However, due to the lack of standardized
methodologies and different scopes, comparison of data reported in the different countries is
difficult due to differences in (a) the bacterial species considered, (b) the geographical and
temporal coverage of each report, (c) the choice of antimicrobials included in the panel for
AST, and d) the methods for antimicrobial susceptibility determination (disk diffusion vs broth
microdilution, clinical breakpoints vs ECOFFs).
EFSA has provided a global state of play for the following bacteria: Staphylococcus
pseudintermedius, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus
schleiferi, Proteus mirabilis, Klebsiella spp., Enterobacter spp., Enterococcus faecalis and Enterococcus
faecium, Bordetella bronchiseptica, Clostridium perfringens and Clostridioides difficile.
Among those bacteria, based on the evidence available and expert opinion, EFSA identified S.
pseudintermedius, E. coli and P. aeruginosa as the most relevant in the EU with > 90% certainty.
Several major data gaps were identified, derived mainly from the lack of information from many
countries in the world (and to a lesser extent from some regions in Europe), the insufficient
information on the origins of the bacterial isolates tested (which could result in unknown selection
biases) and the variety of antimicrobials, methodologies and breakpoints used to generate the data
considered in this assessment.
The impact of the uncertainties deriving from these data gaps on the scientific assessment was
incorporated into the results through expert opinion.
5. Recommendation
Data on AMR in bacterial pathogens are necessary to enhance animal health, promote the rational
use of antimicrobials, and identify specific therapeutic challenges attributable to AMR. The very wide
ranges of AMR percentages observed in pathogenic bacteria isolated from cats and dogs in the same
region or country highlight the difficulties in obtaining reliable and comparable estimates from scientific
publications, which are often based on susceptibility testing of specific (and often biased) strain
collections. National monitoring systems for AMR in diseased animals are only available in a few
countries and there are limitations that hamper the comparability of data reported by different
countries (Mader et al., 2021). Moreover, the few available national reports have a limited geographical
scope when considering the global situation, particularly outside Europe. Nevertheless, among the EU
national reports assessed in this opinion, stable or somewhat decreasing AMR trends were found for
most pathogen–drug combinations. Although the significance of these observations should not be
over-interpreted due to the above-mentioned limitations, assuming that sampling and methodological
biases are relatively constant over time for a given monitoring programme, these longitudinal data can
be helpful to detect the emergence of new antimicrobial resistant phenotypes of clinical importance in
pathogens of cats and dogs, and thus help to guide antimicrobial stewardship. In the future,
standardisation and harmonisation of the methodology employed by national surveillance programmes,
including selection criteria for collecting bacterial isolates and performance of AST, would allow more
meaningful comparisons between countries. Alternatively, access to raw AST data generated by such
programmes could enable analysis of data from different countries using the same interpretive criteria
(clinical breakpoints or epidemiological cut-offs), thereby facilitating identification of geographical
differences in the distribution of specific antimicrobial resistant phenotypes of clinical relevance.
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Abbreviations
3GC third-generation cephalosporin
AHL animal health law
AST antimicrobial susceptibility testing
CLSI Clinical and Laboratory Standards Institute
ECOFF epidemiological cut-off
ELR extensive literature review
ESBL extended-spectrum beta-lactamase
ESC extended-spectrum cephalosporinase
EUCAST European Committee on Antimicrobial Susceptibility Testing
I intermediate
MIC minimum inhibitory concentration
MR methicillin resistance
MRSA methicillin-resistant Staphylococcus aureus
MRSP methicillin-resistant Staphylococcus pseudintermedius
PCR polymerase chain reaction
R resistant
S susceptible
UTI urinary tract infection
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Appendix A – Search strings applied
A.1. Pubmed
A.1.1. Common search string “Antimicrobials”
((“antibiotic”[Title/Abstract] OR “antibiotics”[Title/Abstract] OR “antimicrobial”[Title/Abstract] OR
“antimicrobials”[Title/Abstract] OR “Anti-Bacterial Agents”[MeSH Terms:noexp]) AND (“resistan*”[Title/





“Dog”[Title/Abstract] OR “Dogs”[Title/Abstract] OR “Cat”[Title/Abstract] OR “Cats”[Title/Abstract]
OR “Pets”[Title/Abstract] OR “companion animal”[Title/Abstract] OR “companion animals”[Title/
Abstract] OR “canine”[Title/Abstract] OR “feline”[Title/Abstract] OR “Dogs”[MeSH Terms] OR
“Cats”[MeSH Terms] OR “Pets”[MeSH Terms]
A.1.2.2. “Bacterial species”
A.1.2.2.1. Companion animals
“Enterobacter”[MeSH Terms] OR “Staphylococcus aureus”[MeSH Terms] OR “Staphylococcus
intermedius”[MeSH Terms] OR “Enterococcus faecalis”[MeSH Terms] OR “Enterococcus faecium”[MeSH
Terms] OR “Escherichia coli”[MeSH Terms] OR “Klebsiella pneumoniae”[MeSH Terms] OR “Proteus
mirabilis”[MeSH Terms] OR “Bordetella bronchiseptica”[MeSH Terms] OR “Borrelia burgdorferi”[MeSH
Terms] OR “Clostridium perfringens”[MeSH Terms] OR “Pseudomonas aeruginosa”[MeSH Terms] OR
“Enterobacter”[Title/Abstract] OR “Staphylococcus pseudintermedius”[Title/Abstract] OR
“Staphylococcus schleiferi”[Title/Abstract] OR “Enterococcus faecalis”[Title/Abstract] OR “Enterococcus
faecium”[Title/Abstract] OR “Escherichia coli”[Title/Abstract] OR “Klebsiella pneumoniae”[Title/Abstract]
OR “Proteus mirabilis”[Title/Abstract] OR “Staphylococcus aureus”[Title/Abstract] OR “Bordetella
bronchiseptica”[Title/Abstract] OR “Borrelia burgdorferi”[Title/Abstract] OR “Clostridium difficile”[Title/
Abstract] OR “Clostridium perfringens”[Title/Abstract] OR “Pseudomonas aeruginosa”[Title/Abstract]
A.2. Embase
A.2.1. Common search string “Antimicrobials”
1. antibiotic resistance/or exp antibiotic sensitivity/or exp drug resistance/
2. susceptib*.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
3. resistan*.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
4. 2 or 3
5. antibiotic.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
6. antibiotics.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
7. antimicrobial.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
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8. antimicrobials.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
9. 5 or 6 or 7 or 8
10. antibiotic agent/
11. 10 or 9
12. 11 and 4






3. 1 or 2
4. Dog.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
5. Dogs.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
6. Cat.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
7. Cats.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
8. Canine.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
9. Feline.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
10. “Companion animal”.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
11. “Companion animals”.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
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13. Clostridium perfringens/
14. Pseudomonas aeruginosa/
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. Enterobacter.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
17. Staphylococcus pseudintermedius.mp.
18. Staphylococcus schleiferi.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
19. Enterococcus faecalis.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
20. Enterococcus faecium.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
21. Escherichia coli.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
22. Klebsiella pneumoniae.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
23. Proteus mirabilis.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word]
24. Staphylococcus aureus.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
25. Bordetella bronchiseptica.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
26. Borrelia burgdorferi.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
27. Clostridium difficile.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
28. Clostridium perfringens.mp. [mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word]
29. Pseudomonas aeruginosa.mp. [mp=title, abstract, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword, floating
subheading word, candidate term word]
30. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. 15 or 30
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Appendix B – Excel file with all the data extracted
Information on all the full-text studies that were assessed, including the reason for exclusion for
those that were excluded at the full-text screening and the data extracted from the included studies,
can be consulted at https://doi.org/10.5281/zenodo.4912394.
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Appendix D – Data on proportion of resistance, sorted by country
The figures below show, for each pathogen, the available data on the proportion of resistance
sorted by country. The total number of studies by country and antimicrobial is reported on the right
side. Each circle represents one study and the size of each circle reflects how many isolates were
included in the study. The colour of a circle illustrates whether the proportion represents resistance
only (red circle) or resistance merged with intermediate (blue circle). The dashed lines indicate, for
each antibiotic, the weighted arithmetic mean of % resistance, not taking into account the difference
between %R and %R + I.
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Appendix E – Exact percentages of weighted arithmetic means of %R and

























Fluoroquinolones R 7.4 94.3 1 12.2 S. pseudintermedius
Fluoroquinolones R + I 7.1 13 1 5 S. pseudintermedius
Fusidic acid R + I 12.9 38 0 6.4 S. pseudintermedius
Gentamicin R 7.2 58.6 1 10.3 S. pseudintermedius
Gentamicin R + I 8.3 13.5 1.7 4.6 S. pseudintermedius
Lincosamides R 26 98.6 3.3 17.6 S. pseudintermedius
Lincosamides R + I 19.8 24.9 13 4.6 S. pseudintermedius
Methicillin R 7.7 72.2 0.9 9.5 S. pseudintermedius
Sulfa/TMP R 13.5 97.1 5 10.2 S. pseudintermedius
Tetracyclines R 31.8 95.7 13.7 16.4 S. pseudintermedius
Tetracyclines R + I 23.2 33.8 20.2 4.2 S. pseudintermedius
3GC R 6.5 33.3 0 6.3 E. coli
3GC R + I 11.1 71.4 0.2 10.8 E. coli
Aminopenicillins R 30.7 100 8.8 15.8 E. coli
Aminopenicillins R + I 39.3 70.2 28.1 12.5 E. coli
Amox/Clav R 16.7 100 0 18 E. coli
Amox/Clav R + I 26.5 76.5 12.3 13.2 E. coli
Fluoroquinolones R 14.4 92.5 1.8 14.6 E. coli
Fluoroquinolones R + I 8 39.3 2.1 7.6 E. coli
Nitrofurantoin R + I 1.1 1.6 1 0.2 E. coli
Sulfa/TMP R 11.7 77.5 0 9.5 E. coli
Fluoroquinolones R 34.4 63.6 9 13.8 P. aeruginosa
Fluoroquinolones R + I 62.9 80 8 17.2 P. aeruginosa
Gentamicin R 14.5 71.4 4.1 19.3 P. aeruginosa
Gentamicin R + I 16.2 36.4 2 5 P. aeruginosa
Polymyxin B/
Colistin
R 11.3 54.4 0 14.8 P. aeruginosa
Polymyxin B/
Colistin
R + I 0.8 1 0 0.4 P. aeruginosa
3GC R 14.5 100 9.3 17.4 Klebsiella spp.
3GC R + I 70.2 91.7 0 39.2 Klebsiella spp.
Aminopenicillins R 81.9 91 62.5 13.4 Klebsiella spp.
Amox/Clav R 30.3 50 21 13.7 Klebsiella spp.
Amox/Clav R + I 76.6 91.7 27.3 27.6 Klebsiella spp.
Fluoroquinolones R 49.8 100 12.5 35.8 Klebsiella spp.
Sulfa/TMP R 64.2 91.7 9.1 28.5 Klebsiella spp.
3GC R 8.7 33.3 5.2 9.3 Enterobacter spp.
Sulfa/TMP R 48 97.4 13 41.8 Enterococcus spp.
3GC R 16.2 37 9.4 11.9 Proteus spp.
3GC R + I 3.3 75 1.8 8.5 Proteus spp.
Aminopenicillins R 38.6 71 28 18.6 Proteus spp.
Aminopenicillins R + I 26.1 28.9 8.7 6.9 Proteus spp.
Amox/Clav R 6.3 20.4 3.7 5 Proteus spp.
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Amox/Clav R + I 11.5 68.7 5.5 6.4 Proteus spp.
Fluoroquinolones R 8.5 26.2 0.3 11.5 Proteus spp.
Fluoroquinolones R + I 9.8 13.2 3.6 3.2 Proteus spp.
Sulfa/TMP R 21.2 87.5 5.3 10.1 Proteus spp.
Fluoroquinolones R + I 32.9 52.5 3 22.2 S. schleiferi
Gentamicin R + I 31.2 49 0 23 S. schleiferi
Lincosamides R + I 17.7 25.5 4 10.1 S. schleiferi
Methicillin R 40 67.3 0 29.6 S. schleiferi
Sulfa/TMP R 4.1 10.8 0.9 4.6 S. schleiferi
Tetracyclines R + I 10.6 19 3 8 S. schleiferi
Fluoroquinolones R 11.9 27.5 2.7 10.3 S. aureus
Fluoroquinolones R + I 14 51.3 0 9 S. aureus
Fusidic acid R + I 11.6 74.4 5 17.5 S. aureus
Gentamicin R 7.4 35.3 0 11.5 S. aureus
Gentamicin R + I 15.2 74.4 0 14.7 S. aureus
Lincosamides R 15.5 55.6 1.5 18.4 S. aureus
Lincosamides R + I 28.8 100 23 20.4 S. aureus
Methicillin R 17.8 36.4 0 8.7 S. aureus
Sulfa/TMP R 13.6 100 0 17.7 S. aureus
Tetracyclines R 19.9 38.2 9.4 11.1 S. aureus
Tetracyclines R + I 26.8 60 10 5.4 S. aureus
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